1 Previous studies have shown that cipro¯oxacin and biphenylacetic acid (BPAA) synergistically inhibit g-aminobutyric acid (GABA) A receptors. In the present study, we have investigated the actions of these two drugs on other neuronal ligand-gated ion channels. 2 Agonist-evoked depolarizations were recorded from rat vagus and optic nerves in vitro by use of an extracellular recording technique. 3 GABA (50 mM)-evoked responses, in the vagus nerve in vitro, were inhibited by bicuculline (0.3 ± 10 mM) and picrotoxin (0.3 ± 10 mM), with IC 50 values and 95% con®dence intervals (CI) of 1.2 mM (1.1 ± 1.4) and 3.6 mM (3.0 ± 4.3), respectively, and were potentiated by sodium pentobarbitone (30 mM) and diazepam (1 mM) to (mean+s.e.mean) 168+18% and 117+4% of control, respectively. 5-Hydroxytryptamine (5-HT; 0.5 mM)-evoked responses were inhibited by MDL 72222 (1 mM) to 10+4% of control; DMPP (10 mM)-evoked responses were inhibited by hexamethonium (100 mM) to 12+5% of control, and abMeATP (30 mM)-evoked responses were inhibited by PPADS (10 mM) to 21+5% of control. Together, these data are consistent with activation of GABA A , 5-HT 3 , nicotinic ACh and P2 X receptors, respectively. 4 Cipro¯oxacin (10 ± 3000 mM) inhibited GABA A -mediated responses in the vagus nerve with an IC 50 (and 95% CI) of 202 mM (148 ± 275). BPAA (1 ± 1000 mM) had little or no eect on the GABA A -mediated response but concentration-dependently potentiated the eects of cipro¯oxacin by up to 33,000 times. 5 Responses mediated by 5-HT 3 , nicotinic ACh and P2 X receptors in the vagus nerve and strychninesensitive glycine receptors in the optic nerve were little or unaected by cipro¯oxacin (100 mM), BPAA (100 mM) or the combination of these drugs (both at 100 mM). 6 GABA (1 mM)-evoked responses in the optic nerve were inhibited by bicuculline with an IC 50 of 3.6 mM (2.8 ± 4.5), a value not signi®cantly dierent from that determined in the vagus nerve. Cipro¯oxacin also inhibited the GABA-evoked response with an IC 50 of 334 mM (256 ± 437) and BPAA (100 mM) potentiated these antagonist eects. However, the magnitude of the synergy was 48 times less than that seen in the vagus nerve. 7 These data indicate that cipro¯oxacin and BPAA are selective antagonists of GABA A receptors, an action that may contribute to their excitatory eects in vivo. Additionally, our data suggest that the molecular properties of GABA A receptors in dierent regions of the CNS in¯uence the extent to which these drugs synergistically inhibit the GABA A receptor.
Introduction
Fluoroquinolones, such as cipro¯oxacin and nor¯oxacin, represent an important class of antimicrobial agents used in the treatment of a wide range of infectious diseases (Lietman 1995) . However, these drugs are also associated with a low incidence of adverse eects related to gastrointestinal and central nervous system (CNS) function (Hooper & Wolfson, 1989) . The adverse CNS eects include dizziness, headaches and insomnia (Domagala, 1994) . In addition, convulsions are occasionally observed (Simpson & Brodie, 1985; Anastasio et al., 1988) , an adverse eect that may markedly increase in patients concomitantly prescribed certain non-steroidal anti-in¯ammatory drugs (NSAIDs), particularly fenbufen (Christ, 1990; Janknegt, 1990; Stahlman, 1990; Lietman, 1995) . This is a serious and unwanted clinical eect that has resulted in the Committee on Safety of Medicines (CSM) advising clinicians not to prescribe quinolones together with NSAIDs (CSM, 1991) .
A number of studies have investigated possible mechanisms underlying the adverse CNS actions of quinolones (for review, see Halliwell et al., 1993) . Electrophysiological studies in this and other laboratories have clearly demonstrated that several quinolones, including cipro¯oxacin and nor¯oxacin, are weak antagonists of g-aminobutyric acid (GABA) A -mediated currents in CNS neurones Halliwell et al., 1991; Shirasaki et al., 1991) . However, signi®cantly, the NSAID, biphenyl-acetic acid (BPAA; the active metabolite of fenbufen), whilst having little or no eect itself, potentiates the antagonist eects of cipro¯oxacin (and certain other¯uoroquinolones) at the GABA A receptor by as much as 10,000 times Halliwell et al., 1991; Shirasaki et al., 1991) . Consistent with these ®ndings, radioligand binding studies in human (Motumoro et al., 1991) (Hori et al., 1987; Tsuji et al., 1988; Yamamoto et al., 1988; Akahane et al., 1989; Squires & Saederup, 1993; Domagala, 1994) . It is well established that GABA A antagonists have proconvulsant eects (Matsumoto, 1989; Upton, 1994; Sieghart, 1995) and, therefore, the actions of quinolones in combination with BPAA at the GABA A receptor may contribute to their excitotoxic eects. In keeping with this hypothesis, in animal studies there is a close correlation between the epileptogenic activity of quinolones and BPAA and their potency at inhibiting [ 3 H]-muscimol binding to rodent brain synaptic plasma membranes (Akahane et al., 1989) .
However, although these drugs do not aect ionotropic glutamate receptor-mediated currents in hippocampal neurones Halliwell et al., 1995) , the eects of quinolones and BPAA at other neuronal ligand-gated ion channels are not known. In the present study, therefore, we have utilized an extracellular recording technique to investigate the eects of cipro¯oxacin and BPAA alone, and in combination, on neuronal GABA A , 5-hydroxytryptamine 3 (5-HT 3 ), nicotinic acetylcholine (nicotinic ACh) and P2 X receptors in the rat isolated vagus nerve, and GABA A and glycine receptors in the rat isolated optic nerve. Parts of this study have been published in abstract form (Green et al., 1995) .
Methods
Male Wistar rats (100 ± 350 g, bred in-house) were killed by a rising concentration of CO 2 . The cervical vagus nerves (15 ± 20 mm) and/or the optic nerves (circa 8 ± 12 mm long) were quickly dissected free. The connective tissue sheath which surrounds the vagus nerve bundle was removed. Each nerve was mounted onto a microscope slide straddling across a thin (&2 mm wide) seam of silicone grease. A further seam of silicone grease was layered over the ®rst, essentially bissecting the nerve into two equal halves on the slide. The preparation was then placed on to a`Perspex' holder housed inside à Faraday' cage.
Electrophysiological recordings
Silver-silver chloride recording electrodes (RC1, Clarke Electromedical), were placed onto the slide on either side of the grease-gap and secured by brackets onto the Perspex frame. Agonist-evoked changes in d.c. potential across the recording electrodes were relayed through miniature coaxial cable to a Neurolog AC-DC ampli®er (NL106) and the signal ®ltered (d.c.750 Hz) by a Neurolog ®lter unit (NL125). The recordings were displayed on a¯at-bed pen chart recorder (Kipp & Zonen, BD111 or Ross Instruments, MDL 202) . Agonists, which were dissolved in the recording solution, were applied to one side of the nerve via the perfusion system for approximately 2 min, once every 12 min to evoke a change in membrane polarization (the agonist-evoked response). Control experiments demonstrated that this protocol allowed the recording of stable and reproducible responses.
Drugs and solutions
The two sides of the nerves were separately superfused, at 2 ml min 71 , with a physiological recording solution gassed with O 2 and composed of the following (in mM): NaCl 118.0, KH 2 PO 4 1.18, KCl 4.7, MgSO 4 1.18, CaCl 2 2.5, glucose 11.0 and HEPES 10.0. This solution was brought to pH 7.2 by the addition of NaOH. All drugs were applied to the nerve through the superfusion system.
Stock solutions of GABA (1 M), glycine (1 M), 1,1-dimethyl-4-phenylpiperazinium (DMPP, 1 mM), hexamethonium (1 M) and strychnine (1 mM), which were obtained from Sigma, were initially dissolved in twice-distilled deionized water and then further diluted to the required concentrations in the recording solution. a,b-Methylene adenosine 5' triphosphate (abMeATP, 10 mM), 5-hydroxytryptamine (5-HT, 10 mM), picrotoxin (1 mM) and sodium pentobarbitone (10 mM) (all obtained from Sigma) were dissolved in the recording solution. Pyridoxal phosphate-6-azophenyl-2'4'-disulphonic acid (PPA DS) and MDL 72222 (3-tropanyl-3-5-dichlorobenzoate) were obtained from Research Biochemicals and were also dissolved in the recording solution to give stock solutions of 1 mM. Ci-pro¯oxacin (Bayer) was dissolved as a stock solution (at 10 mM) in twice-distilled deionized water and then diluted into the recording solution to the required concentrations. BPAA (Sigma) was made up as a stock solution of 100 or 300 mM in absolute ethanol and then diluted in the recording solution. The ®nal concentration of ethanol did not exceed 0.1%, a concentration which had no eect on the response to GABA in control experiments. Diazepam (Roche) was ®rst dissolved in 0.1 ml ethanol and then diluted in recording solution to form a 1 mM stock solution. Bicuculline (Sigma) was ®rst dissolved in 0.1 ml conc. HCl to which twice-distilled deionised water was added to form a stock solution of 1 mM. Bicuculline was then diluted in the recording solution at the required concentrations. All salts, which were of analytical grade, were purchased from British Drug Houses.
Experimental protocol
Concentration-response curves to each of the agonists were obtained from which the EC 50 value (+95%CI) was interpolated. A concentration of each agonist approximating its EC 50 was then used in further selectivity studies. Three control agonist-evoked responses were obtained and then three further agonist-evoked responses were determined in the presence of each antagonist/modulator concentration. Pilot experiments demonstrated that all compounds produced their maximal eect after 20 min in contact with the preparations. All drug eects were therefore tested after 20 min contact time.
Data analysis
Agonist-evoked responses were measured at their peak amplitude and are expressed as the arithmetic mean (+s.e.mean of n experiments) of the response before the addition of any drugs. The data were pooled and log[agonist]-response plots and log[antagonist]-response plots ®tted with a sigmoidal function by use of an automated least squares curve ®tting routine (Graphpad Prism v2.0) to determine EC 50 and IC 50 (+95% CI) values. Control concentration-response curves to agonists were normalized by expressing all responses relative to the maximal response evoked for each agonist. Statistical comparisons of the data were carried out by use of one way ANOVA followed by Newman-Keuls Multiple Comparison post hoc test running on Graphpad Prism.
Results
Pharmacological characteristics of agonist-evoked responses in the rat vagus nerve in vitro GABA (3 ± 3000 mM), 5-HT (0.01 ± 10 mM), DMPP (3 ± 100 mM) and abMeATP (1 ± 300 mM) each evoked concentration-dependent depolarizations of the isolated vagus nerve with EC 50 values (and 95% Cl) of 69 mM (55 ± 87, n=21), 0.8 mM (0.5 ± 1.0, n=9), 13 mM (8 ± 22, n=7) and 26 mM (19 ± 34, n=4), respectively (see Figure 1 ).
Responses to GABA (50 mM) were inhibited by bicuculline (0.3 ± 10 mM) and picrotoxin (0.3 ± 10 mM) with IC 50 values (and 95% Cl) of 1.2 mM (1.1 ± 1.4, n=3 ± 12) and 3.6 mM (3.0 ± 4.3, n=3 ± 5), respectively. GABA-evoked responses were potentiated by the barbiturate, sodium pentobarbitone (30 mM), and the benzodiazepine, diazepam (1 mM), to (mean+s.e. mean) 168+18% (n=6) and 117+4% (n=7) of control, respectively (not shown). These data are therefore consistent with GABA activating the GABA A receptor.
5-HT (0.5 mM)-evoked responses were inhibited by MDL 72222 (1 mM) to 10+4% (n=5) of control, consistent with activation of the 5-HT 3 receptor. The DMPP (10 mM) responses were inhibited by hexamethonium (100 mM) to 12+5% (n=4) of control, consistent with activation of a ni-cotinic ACh receptor. The abMeATP (30 mM) response was inhibited by PPADS (10 mM) to 21+5% (n=4) of control, consistent with activation of a P2 X receptor ( Figure 3 ).
Together, these data are in agreement with those of others recording from vagus nerves by use of extracellular techniques (Ireland & Tyers, 1987; Marsh, 1989; Trezise et al., 1994) .
The eects of cipro¯oxacin and BPAA on GABA A , 5-HT 3 , nicotinic ACh and P2 X receptors in the vagus nerve Cipro¯oxacin (10 ± 3000 mM) weakly, but concentration-dependently inhibited GABA A -mediated responses with an IC 50 (and 95% Cl) of 202 mM (148 ± 275). BPAA (1 ± 1000 mM) had little or no eect on the GABA-evoked response but potentiated the antagonist eects of cipro¯oxacin in a concentrationdependent fashion (see Figure 2 ). For example, in the presence of BPAA (300 mM), the IC 50 for cipro¯oxacin was reduced by more than 33,000 times to 6 nM (see Table 1 ). The eects of all drugs were reversible on wash.
In contrast, neither cipro¯oxacin (100 mM), BPAA (100 mM) nor the combination of these drugs (both at 100 mM) greatly Selective antagonism of GABA A receptors aected 5-HT 3 -, nicotinic ACh-or P2 X -mediated responses (see Figure 3 ).
Pharmacological characteristics of agonist-evoked responses in the rat optic nerve in vitro
Glycine (30 mM ± 10 mM) and GABA (30 mM ± 10 mM) evoked concentration-dependent depolarizations of the isolated optic nerve with EC 50 values (and Cl) of 1.7 mM (1.4 ± 2.2, n=16), and 1.1 mM (1.0 ± 1.2, n=6), respectively (see Figure 4 ). Bicuculline (0.3 ± 30 mM) inhibited GABA (1 mM)evoked responses with an IC 50 of 3.6 mM (2.8 ± 4.5, n=4 ± 7). An overall one way analysis of variance followed by post hoc analysis indicated that the antagonist eects of bicuculline were not dierent between the vagus and optic nerves (F=0.86, P50.05). Bicuculline (10 mM) had little or no effect on the response to glycine (1 mM). In contrast, strychnine (3 mM) antagonized glycine responses to 16+7% (n=4), but had little or no eect on the response to GABA (1 mM). These control data are consistent with those obtained previously by Simmonds (1983) .
The eects of cipro¯oxacin and BPAA on GABA A and glycine receptors in the optic nerve
Cipro¯oxacin inhibited GABA-evoked responses with an IC 50 of 334 mM (256 ± 437, n=4 ± 6). The concentration-inhibition relationship for cipro¯oxacin against the GABA-evoked response was not signi®cantly dierent between the two nerves (P50.05). BPAA (1 ± 300 mM) had little or no eect on the The IC 50 value of cipro¯oxacin (CFLX) alone against the GABA (50 mM)-evoked response and its IC 50 when BPAA was co-applied, at the concentrations shown, are presented. The shift in the potency is the IC 50 value of cipro¯oxacin alone, divided by its IC 50 in the presence of BPAA. GABA-evoked response. However, BPAA (100 mM) potentiated the antagonist eects of cipro¯oxacin at the GABA A receptor by 84 times, a value 48 times less than that seen in the vagus nerve with this combination of drugs (see Figure 5 ). Strychnine-sensitive glycine responses were little or unaected by cipro¯oxacin (100 mM), BPAA (100 mM) or the combination of these drugs (both at 100 mM): the responses were 113+8% (n=5), 89+5% (n=4) and 107+5% (n=8) of control, respectively (see Figure 4 ).
Discussion
The present study has shown that cipro¯oxacin is a weak antagonist of GABA A receptor-mediated responses in the rat isolated vagus nerve. Our experiments also show that BPAA, whilst having little or no eect itself at the GABA A receptor, potentiates the antagonist eects of cipro¯oxacin by up to 33,000 times. These data are consistent with previous electrophysiological studies of the eects of these drugs on GABAevoked whole cell currents recorded from rat and frog single dorsal root ganglion neurones (Halliwell et al., 1991; Yakushijii et al., 1992) and rat hippocampal neurones Halliwell et al., 1995) . In addition, our ®ndings are in keeping with radioligand binding experiments demonstrating that these drugs synergistically inhibit the binding of [ 3 H]-GABA and [ 3 H]-muscimol to rodent brain synaptic plasma membranes (Hori et al., 1987; Tsuji et al., 1988; Yamamoto et al., 1988; Akahane et al., 1989) . Squires and Saederup (1993) have also shown that¯uoroquinolones, including cipro¯oxacin, reverse the inhibitory eect of GABA on [ 35 S]-TBPS binding and that this action is most markedly enhanced by BPAA, when compared with other NSAIDs. Taken together, these data are remarkably consistent and support the use of the isolated vagus nerve as a simple model with which to investigate the pharmacological properties of neuronal GABA A receptors. The present study also demonstrates, for the ®rst time, that cipro¯oxacin and BPAA have little or no eect at 5-HT 3 , nicotinic ACh or P2 X receptors in the vagus nerve or strychninesensitive glycine receptors in the optic nerve. These data, together with previous radioligand binding and electrophysiological experiments showing that such drugs have no eect on ionotropic glutamate receptors (Dodd et al., 1989; Nozaki et al., 1990; Shirasaki et al., 1991; Halliwell et al., 1995) , indicate that cipro¯oxacin together with BPAA are highly selective antagonists of neuronal GABA A receptors. In addition, ci-pro¯oxacin alone does not in¯uence the binding of speci®c ligands to muscarinic cholinoceptors, b-adrenoceptors, naloxone-sensitive opiate or imipramine sites in rat CNS membranes (Segev et al., 1988) . These compounds may, therefore, prove useful and selective tools for the investigation of GABA A receptors, although their eects have not yet been determined on voltage-gated ion channels or several other second messengercoupled receptors.
At the present time, the mechanism of the synergy between cipro¯oxacin and BPAA is unclear. Two hypotheses currently under investigation are: (a) that there is an intermolecular interaction between the quinolone and BPAA resulting in a molecule more active at the receptor and (b) that a novel binding site exists for the NSAID on the GABA A receptor complex. Evidence for both hypotheses has been presented. Thus, Akahane and colleagues have shown that a hybrid molecule, which¯exibly links noroxacin with BPAA, is a potent antagonist of [ 3 H]-muscimol binding and 36 Cl 7 uptake in rat synaptic membranes, and also of GABA-activated whole cell currents recorded from rat hippocampal neurones. In contrast, a hybrid molecule linking nor¯oxacin with BPAA via a less¯exible bridge had little eect Imanishi et al., 1996; Ito et al., 1996) . These data were interpreted to indicate an intermolecular interaction between the quinolone and BPAA at the GABA A binding site. However, these data do not rule out a separate binding site for BPAA which cannot be accessed when it is rigidly and closely linked to nor¯oxacin. Indeed, nor¯oxacin (and ci-pro¯oxacin) bind to their own (possibly the GABA binding) site and, therefore, this interaction would hinder the association of BPAA to other sites on or around the receptor. It is clearly of interest to determine if quinolones and NSAIDs interact with distinct binding sites on the GABA A receptor complex.
With reference to the second hypothesis, Squires and Saederup (1993) have, on the basis of [ 35 S]-TBPS binding studies, suggested that nor¯oxacin and related piperazinoquinolones, acting at GABA A receptors, induce a high anity binding site for BPAA-like NSAIDs that when occupied, reciprocally increases the anities of the quinolones for GABA A receptors. This site is postulated to be a new site on the GABA A receptor complex. Our present data are not inconsistent with a speci®c binding site for BPAA because the magnitude of the synergy was approximately 50 times less in the optic nerve than in the vagus nerve. The molecular (subunit?) properties of the GA-BA A receptor complex may therefore in¯uence the interaction of quinolone/NSAIDs at GABA A receptors. Interestingly, Motomura and colleagues (1991) have shown that enoxacin and fenbufen synergistically inhibit [ 3 H]-muscimol binding to mouse and human hippocampal and cortical membranes, but do not synergistically inhibit muscimol binding to cerebellum membranes. These data, along with our own results, are the ®rst evidence for regional dierences in the magnitude of the synergy across the CNS. Speculatively, these molecules may thus prove useful probes with which to identify dierent GA-BA A receptor isoforms. Fluoroquinolones alone and, more especially, used in combination with certain NSAIDs (e.g. fenbufen) are associated with a number of unwanted neurological eects in both animals and man (most seriously convulsions, Hori et al., 1987; Akahane et al., 1989; Christ, 1990; Giardina, 1991; Leitman, 1995) . This interaction is probably not the result of a pharmacokinetic interaction between these drugs in vivo (Fillastre et al., 1993; Tsutomi et al., 1994) , but may be related to their selective antagonism of neuronal GABA A receptors. Consistent with this possibility, in ddY mice that develop clonic convulsions following administration of cipro¯oxacin (40 mg kg 71 ) and BPAA (50 mg kg 71 ), brain concentrations were 1 mM and 25 mM, respectively . These concentrations were also shown to reduce [ 3 H]-muscimol binding to synaptic plasma membranes by circa 30%, suggesting that a reduction of GABA A receptor function of 30% may result in convulsions. Moreover, when brain concentra-tions of cipro¯oxacin reached 2.5 mM, achieved with 100 mg kg 71 cipro¯oxacin, convulsions and subsequent death occurred in all mice tested; this concentration of cipro¯oxacin (in the presence of BPAA [50 mg kg 71 ]) inhibited [ 3 H]-muscimol binding by 45% . Interestingly, the hybrid molecule of nor¯oxacin and BPAA (discussed above) has been shown to induce clonic seizures and subsequent death in mice when injected intracisternally at doses as low as 0.1 nmol . These agents may therefore prove useful in the study of seizure mechanisms.
In conclusion, the present study shows that cipro¯oxacin and BPAA synergistically and selectively inhibit GABA A receptors. The mechanism underlying this novel synergy is presently not understood, but the magnitude may be in¯uenced by the properties of the GABA A receptor complex.
